Current Knowledge of MicroRNAs (miRNAs) in Acute Coronary Syndrome (ACS): ST-Elevation Myocardial Infarction (STEMI)

Gosav, Evelina Maria; Ouatu, Anca; Bădescu, Magda; Dima, Nicoleta; Ganceanu-Rusu, Ana Roxana; Popescu, Dan; Floria, Mariana; Rezuş, Elena; Rezuş, Ciprian

doi:10.3390/life11101057

Cited by 12 publications

(9 citation statements)

References 181 publications

(207 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The mechanism of miRNAs action is based on the inhibition of protein translation process or direct degradation of mRNA of the target genes through binding of miRNAs to the complementary region of the target mRNA molecule [ 130 ]. Much data is available confirming the participation of miRNAs in the process of physiological regulation of the heart function and also in the progression of cardiovascular diseases [ 131 , 132 , 133 , 134 ].…”

Section: Ncrnas As the Modulators Of Lgals3 Gene Expression And A New Potential Therapeutic Targetmentioning

confidence: 99%

The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases

2021

View full text Add to dashboard Cite

Galectin-3 plays a prominent role in chronic inflammation and has been implicated in the development of many disease conditions, including heart disease. Galectin-3, a regulatory protein, is elevated in both acute and chronic heart failure and is involved in the inflammatory pathway after injury leading to myocardial tissue remodelling. We discussed the potential utility of galectin-3 as a diagnostic and disease severity/prognostic biomarker in different cardio/cerebrovascular diseases, such as acute ischemic stroke, acute coronary syndromes, heart failure and arrhythmogenic cardiomyopathy. Over the last decade there has been a marked increase in the understanding the role of galectin-3 in myocardial fibrosis and inflammation and as a therapeutic target for the treatment of heart failure and myocardial infarction.

show abstract

Section: Ncrnas As the Modulators Of Lgals3 Gene Expression And A New Potential Therapeutic Targetmentioning

confidence: 99%

The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases

2021

View full text Add to dashboard Cite

show abstract

“…CDR132L, presently slated for phase II trials, may become the premier microRNA-targeting medication in cardiovascular therapy. [ 99 , 100 , 101 , 102 , 103 , 104 , 105 , 106 , 107 , 108 , 109 , 110 , 111 , 112 , 113 , 114 , 115 , 116 , 117 , 118 , 119 , 120 , 121 , 122 , 123 ]…”

Section: Searching Roles Of Micrornas In the Cardiovascular Systemmentioning

confidence: 99%

The Roles of microRNAs in the Cardiovascular System

Nappi,

Avtaar Singh,

Jitendra

et al. 2023

IJMS

View full text Add to dashboard Cite

The discovery of miRNAs and their role in disease represent a significant breakthrough that has stimulated and propelled research on miRNAs as targets for diagnosis and therapy. Cardiovascular disease is an area where the restrictions of early diagnosis and conventional pharmacotherapy are evident and deserve attention. Therefore, miRNA-based drugs have significant potential for development. Research and its application can make considerable progress, as seen in preclinical and clinical trials. The use of miRNAs is still experimental but has a promising role in diagnosing and predicting a variety of acute coronary syndrome presentations. Its use, either alone or in combination with currently available biomarkers, might be adopted soon, particularly if there is diagnostic ambiguity. In this review, we examine the current understanding of miRNAs as possible targets for diagnosis and treatment in the cardiovascular system. We report on recent advances in recognising and characterising miRNAs with a focus on clinical translation. The latest challenges and perspectives towards clinical application are discussed.

show abstract

“…MicroRNAs (miRNAs) are a class of ncRNAs that regulate gene expression posttranscriptionally (14). These small ncRNAs are single-stranded RNAs, 19-24 nucleotides in length (15). So far, the miRBase data set (version 22) counts 1917 miRNA precursors and 2656 mature miRNAs in humans (16).…”

Section: Biogenesis and Functions Of Mirnasmentioning

confidence: 99%

“…Although primarily localized intracellularly, miRNAs are also detected in extracellular fluids (plasma, serum, cerebrospinal fluid, urine, saliva, breast milk) originating from damaged or living cells (14,15). Considering the availability of blood as a sample, circulating miRNAs are being intensively investigated as potential biomarkers in the diagnosis and prognosis of cardiovascular and other diseases (22).…”

Section: Biogenesis and Functions Of Mirnasmentioning

confidence: 99%

Circulating non-coding RNAs as biomarkers in coronary artery disease

Petković¹,

Erceg²,

Munjas³

et al. 2022

Arhiv za farmaciju

View full text Add to dashboard Cite

Coronary artery disease (CAD) is a leading cause of mortality worldwide. Atherosclerosis involves an interplay of different pathological mechanisms, such as progressive inflammation, abnormal lipid metabolism, and oxidative stress, and as such represents the basic pathological phenomenon underlying CAD. Atherosclerotic plaque narrows the lumen of coronary arteries, creating an ischemic environment for the heart muscle, which finally leads to clinical complications, such as acute myocardial infarction. Currently, there are no biomarkers that could predict plaque stability or major adverse cardiovascular events (MACE). Numerous functional non-coding RNA (ncRNA) species influence basic cellular functions, and as such play a role in the development and progression of CAD. Of these ncRNAs, micro RNAs (miRNAs) and long non-coding RNAs (lncRNAs) are the most investigated. Considering that ncRNAs detected in extracellular fluids can originate from different cells, circulating ncRNAs are being intensively investigated as potential biomarkers in the diagnosis and prognosis of CAD. In the following paper, we provide current insights into potential molecular mechanisms by which miRNAs and lncRNAs contribute to the pathology of CAD and discuss their potential role as biomarkers in diagnosis and prognosis of disease.

show abstract

Current Knowledge of MicroRNAs (miRNAs) in Acute Coronary Syndrome (ACS): ST-Elevation Myocardial Infarction (STEMI)

Cited by 12 publications

References 181 publications

The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases

The Diagnostic and Therapeutic Potential of Galectin-3 in Cardiovascular Diseases

The Roles of microRNAs in the Cardiovascular System

Circulating non-coding RNAs as biomarkers in coronary artery disease

Contact Info

Product

Resources

About